Filtered By:
Drug: Taxotere
Countries: Australia Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 10 results found since Jan 2013.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT02446405, ANZCTR, ACTRN12614000110684, and EudraCT, 2014-003190-42.FINDINGS: Between March 31, 2014, and March 24, 2017, 1125 participants were randomly assigned to receive non-steroidal antiandrogen (n=562; control group) or enzalutamide (n=563). The median age was 69 years (IQR 63-74). This analysis was triggered on Jan 19, 2022, and an updated survival status identified a total of 476 (42%) deaths. After a median follow-up of 68 months (IQR 67-69), the median overall survival was not reached (hazard ratio 0·70 [95% CI 0·58-0·84]; p<0·0001), with 5-year overall ...
Source: Cancer Control - March 29, 2023 Category: Cancer & Oncology Authors: Christopher J Sweeney Andrew J Martin Martin R Stockler Stephen Begbie Leanna Cheung Kim N Chi Simon Chowdhury Mark Frydenberg Lisa G Horvath Anthony M Joshua Nicola J Lawrence Gavin Marx John McCaffrey Ray McDermott Margaret McJannett Scott A North Franc Source Type: research
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial
CONCLUSIONS: Overall, no significant differences in survival were found amongst the studied regimens after a long-term observational period.TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12610000151033.PMID:35610366 | DOI:10.1038/s41416-022-01846-y
Source: Cancer Control - May 24, 2022 Category: Cancer & Oncology Authors: Flora Zagouri Georgia-Angeliki Koliou Foteinos Dimitrakopoulos Christos Papadimitriou Ioannis Binas Angelos Koutras Pavlos Papakostas Christos Markopoulos Vasileios Venizelos Grigorios Xepapadakis Αngeliki Andrikopoulou Charisios Karanikiotis Amanda Psyr Source Type: research
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel < em > versus < /em > standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
CONCLUSION: The results of this trial will generate data on the clinical utility of mGSTP1 as a novel biomarker to guide treatment de-escalation in metastatic CRPC.PMID:35465297 | PMC:PMC9019311 | DOI:10.1177/17588359221092486
Source: Adv Data - April 25, 2022 Category: Epidemiology Authors: Ciara Conduit Blossom Mak Wenjia Qu Juliana Di Lulio Ronan Burder Matthias Bressel Thomas Cusick Haryana M Dhillon Richard De Abreu Louren ço Craig Underhill Javier Torres Megan Crumbaker Florian Honeyball Anthony Linton Ray Allen Ian D Davis Susan J Cla Source Type: research
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis
CONCLUSION: This retrospective multicenter analysis demonstrates the variation in treatment sequences used for mCRPC in the real-world setting. In the absence of high quality, prospective evidence, our results suggest that subsequent treatment choice does not influence survival outcomes and the optimal choice is guided by individual patient and disease-related factors.PMID:35098653 | DOI:10.1111/ajco.13732
Source: Clinical Prostate Cancer - January 31, 2022 Category: Cancer & Oncology Authors: Grace Chazan Angelyn Anton Shirley Wong Julia Shapiro Andrew Weickhardt Arun Azad Edmond M Kwan Lavinia Spain Ashray Gunjur Javier Torres Phillip Parente Francis Parnis Jeffrey Goh Peter Gibbs Ben Tran Source Type: research
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
CONCLUSION: Systemic therapies available for advanced sarcomas have limited activity in EHE. The identification of new active compounds, especially for rapidly progressive cases, is acutely needed.PMID:33713582 | DOI:10.1002/cam4.3807
Source: Methods of Information in Medicine - March 13, 2021 Category: Information Technology Authors: Anna M Frezza Vinod Ravi Salvatore Lo Vullo Bruno Vincenzi Francesco Tolomeo Tom Wei-Wu Chen Pawel Teterycz Giacomo G Baldi Antoine Italiano Nicolas Penel Antonella Brunello Florance Duffaud Nadia Hindi Shintaro Iwata Alannah Smrke Alexander Fedenko Hans Source Type: research
